INCB Export Authorization and UN Single Convention Compliance for Medical Cannabis Shipments

Every cross-border shipment of medical cannabis is a controlled substance transaction governed by international law. Thailand, Germany, Australia, the UK, the Netherlands, and virtually every other country involved in medical cannabis trade are parties to the UN Single Convention on Narcotic Drugs (1961), as amended by the 1972 Protocol. The Convention requires that both the exporting and importing country authorize each shipment through a designated national competent authority. Getting this authorization sequence right is not optional and not procedural: errors result in shipment seizure, destruction of product, and potential criminal liability.

The International Legal Framework

The UN Single Convention on Narcotic Drugs (1961) classifies cannabis as a Schedule I and Schedule IV narcotic substance, permitting its use only for medical and scientific purposes under strict national control. Article 31 of the Convention requires that each shipment of a narcotic substance be authorized by both the exporting country and the importing country, with documentation confirming the medical or scientific purpose of the shipment, the identity and licensing status of the shipper and receiver, and the quantity and form of the substance. The International Narcotics Control Board (INCB), an independent treaty body established under the Convention, monitors global trade in controlled substances and issues import and export authorizations for each transaction.

Thai Export Authorization: The ONCB Process

In Thailand, export of medical cannabis requires authorization from the Office of the Narcotics Control Board (ONCB), in addition to the TFDA export license and DTAM licensing requirements. The ONCB process requires: valid DTAM licenses and authorizations held by the exporting entity; the import permit from the destination country's competent authority, which must be obtained before ONCB authorization can be issued; product specification details including cannabis variety, THC and CBD content by percentage, product form (flower, extract, oil), and quantity in grams or kilograms; details of the licensed Thai exporter and the licensed foreign importer; and documentation of the medical purpose of the shipment. ONCB authorization is issued per shipment, not as a blanket annual authorization. Lead times are typically 10 to 15 business days once all required documentation is complete and consistent.

Destination Country Import Permits

Destination countries issue import permits through their designated national competent authorities under the UN Single Convention framework. In Germany, the competent authority is BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte). In Australia, it is the Office of Drug Control (ODC) within the Department of Health. In the United Kingdom, it is the Home Office Drugs and Firearms Licensing Unit. In the Netherlands, it is the Bureau Medicinale Cannabis (BMC). Each authority has its own application procedures, timelines, and documentation requirements, but all require essentially the same core information: licensed importer details, licensed exporter details, product specification, quantity, intended medical use, and confirmation that the shipment complies with both countries' national narcotics laws.

Import permit applications in destination countries typically take 2 to 6 weeks from submission. The critical sequencing requirement is that the ONCB export authorization cannot be issued until the destination country import permit is confirmed. This means import permit applications must be initiated 4 to 8 weeks before the intended shipment date, and the ONCB authorization process cannot begin in parallel — it must begin after the import permit is in hand.

Common Failures and How to Avoid Them

The most common compliance failure is initiating the ONCB authorization process before the import permit is confirmed, under commercial pressure to meet a shipment date. The ONCB will not issue authorization without the import permit reference, and the attempt simply delays the process further. The second most common failure is documentation inconsistency: the product description, quantity, and party details on the ONCB authorization must match exactly with the import permit and the commercial invoice. A discrepancy — even a minor one such as a different unit (grams versus kilograms) or a different product description format — can result in customs hold or seizure at the destination. The third common failure is underestimating import permit lead times, particularly for first shipments to a new destination where the importer is going through their permit process for the first time with Thai-origin product. DeeMED manages the complete INCB documentation cycle for medical cannabis export shipments, coordinating ONCB authorization, import permit sequencing, and documentation consistency across all elements of the shipment file.